On Nov. 2, 2020, the Drug Enforcement Administration (DEA) published notice of a new Proposed Rule, “Suspicious Orders of Controlled Substances,” to “clarify the procedures a registrant must follow for orders received under suspicious circumstances.” 85 Fed. Reg. 69282, 69284 (“Proposed Rule”).
DEA’s purported “clarification” of those obligations, however, includes an entirely new framework that not only is inconsistent with prior DEA guidance as to registrants’ suspicious order reporting obligations, but more fundamentally represents a lost opportunity to achieve meaningful change. It remains to be seen whether the extended public comment period for the Proposed Rule will be further extended, however, a more comprehensive solution, one that unites disparate stakeholders and data sets in a committed public-private partnership, is necessary to stem the ongoing opioid epidemic.
DEA’s Prior Guidance Has Created a Lack of Uniform Industry Standards that Undermines Data Utility
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
